IGF-1 LR3, also written Long R3 IGF-1, is a laboratory-engineered analog of insulin-like growth factor 1 that differs from the native hormone by two deliberate structural edits: an arginine-for-glutamic-acid swap at position 3 and a 13-amino-acid peptide added to the N-terminus. Those changes raise the chain from 70 to 83 residues and sharply cut its affinity for the IGF binding proteins that normally hold the hormone in reserve, so the analog stays free and active far longer in cell-culture settings. It is manufactured by recombinant DNA technology, is most established as a cell-culture reagent, and holds no approval as a human therapeutic; it is prohibited in competitive sport.
| Feature | Native IGF-1 | IGF-1 LR3 |
|---|---|---|
| Chain length | 70 amino acids | 83 amino acids |
| Position 3 residue | Glutamic acid | Arginine |
| N-terminal extension | None | 13-residue peptide |
| Binding-protein affinity | High | Sharply reduced |
| Receptor target | Type 1 IGF receptor | Type 1 IGF receptor |
IGF-1 LR3 is a synthetic 83-amino-acid analog of the 70-residue native IGF-1, modified by an arginine substitution at position 3 and a 13-residue N-terminal extension that together reduce its binding-protein affinity, and it holds no human-therapeutic approval.
Native insulin-like growth factor 1 is the body's own growth mediator, a single-chain polypeptide of 70 amino acids weighing roughly 7.6 kilodaltons and folded by three disulfide bonds into a shape closely homologous to proinsulin. The liver produces most of it under the drive of pituitary growth hormone, and much of the growth-promoting action credited to growth hormone is in fact carried out through IGF-1 as the downstream signal. Almost none of it travels free; the large majority circulates locked in a ternary complex with binding protein 3 and an acid-labile subunit, a reservoir that meters how much active hormone reaches target tissues.
Native IGF-1 is a 70-amino-acid, roughly 7.6-kilodalton polypeptide produced mainly in the liver under growth-hormone control, and it circulates almost entirely bound to IGF binding proteins that regulate its activity.
The name itself encodes both edits, and neither is arbitrary. The R3 element is a single substitution at position 3 of the mature chain, where the native glutamic acid is replaced with arginine, swapping an acidic residue for a basic one right inside the region that governs binding-protein contact. The Long element is a genetic fusion that adds a 13-amino-acid extension peptide to the N-terminus, and the two edits are complementary; in combination they lower binding-protein affinity far more than either would alone.
The Long R3 modification combines a glutamic-acid-to-arginine substitution at position 3 with a 13-amino-acid N-terminal extension peptide, while leaving the receptor-binding surface and disulfide bonds of native IGF-1 intact.
The cleanest single-number summary of the structural difference is the residue count: 70 for the native hormone against 83 for the analog, a gap of exactly 13. That entire 13-residue difference comes from the N-terminal extension, since the position-3 arginine swap changes one residue's identity but not the total. In mass terms the change runs from roughly 7.6 to about 9.1 kilodaltons.
IGF-1 LR3 contains 83 amino acids to native IGF-1's 70, a difference of exactly 13 residues contributed entirely by the N-terminal extension, raising the molecular weight from roughly 7.6 to about 9.1 kilodaltons.
IGF binding proteins are a family of six carrier proteins that hold the great majority of circulating IGF-1 in a bound, inactive reservoir and release it only in metered amounts. The LR3 structure is engineered to slip past that control: the arginine substitution at position 3 sits within the N-terminal contact surface, and trading an acidic residue for a basic one weakens the interaction, while the added extension further changes how that end of the molecule presents. Because the balance between bound and free hormone decides how much is available at any moment, a molecule that binds the carriers poorly stays disproportionately in the free, receptor-available state.
The glutamic-acid-to-arginine substitution at position 3 and the N-terminal extension together weaken IGF-1 LR3's contact with the IGF binding proteins, sharply reducing carrier affinity and leaving the analog predominantly in the free, receptor-available state.
The half-life gap turns on the binding proteins, not on how fast either molecule is chemically broken down. Free, unbound native IGF-1 clears within roughly ten minutes, and the body only extends its residence by storing most of it in the binding-protein complex; IGF-1 LR3 instead stays free yet persists, with reported figures placing its half-life in the range of many hours. These numbers warrant caution, since they vary by experimental system, species, and method, and figures quoted in non-clinical or commercial settings are not equivalent to controlled human pharmacokinetic data.
| Criteria | Native IGF-1 (free) | IGF-1 LR3 |
|---|---|---|
| Reported half-life | ~10 minutes | Many hours (reported) |
| Route to persistence | Stored in binding-protein complex | Stays free and unsequestered |
| Data quality | Varies; largely non-clinical | Varies; non-clinical or commercial |
Free native IGF-1 clears in roughly ten minutes while IGF-1 LR3 is reported to persist for many hours by evading the binding proteins rather than being stored by them, though these figures come from non-clinical settings and are not controlled human pharmacokinetic data.
The receptor target does not change with the modification. LR3 leaves native IGF-1's receptor-binding residues intact, so it engages and activates the same type 1 IGF receptor, a transmembrane tyrosine kinase, rather than a different one. The apparent rise in potency often seen with LR3 is not evidence that it hits the receptor harder; it reflects that far more of the analog stays free and available because the binding proteins are not sequestering it.
IGF-1 LR3 preserves native IGF-1's receptor-binding surface and activates the same type 1 IGF receptor, and its greater apparent potency comes from more of the analog staying free rather than from stronger receptor engagement.
IGF-1 LR3 is produced by recombinant DNA technology rather than extracted from a natural source, since the engineered 83-residue sequence does not occur in nature. A host expression system, most commonly Escherichia coli chosen for high yield and low cost, carries the gene through expression, refolding, and purification. The best-documented and most transparent commercial use of the finished material is as a supplement in mammalian cell-culture media, where its resistance to binding proteins makes it a stable growth factor for cultured cells.
IGF-1 LR3 is manufactured by recombinant DNA technology, typically expressed in Escherichia coli and then refolded and chromatographically purified, and its best-documented commercial role is as a growth-factor supplement in mammalian cell-culture media.
IGF-1 LR3 is not an approved human therapeutic; no major regulatory authority has cleared it as a drug, and it has not passed the approval process that would establish human safety and efficacy. Commercially it is positioned as a research reagent or cell-culture supplement, labeled for laboratory or research use only and not for human consumption. In competitive sport it is expressly prohibited both in and out of competition, and it does not qualify as a lawful dietary supplement.
IGF-1 LR3 holds no human-therapeutic approval from any major regulatory authority, is sold only as a research-use-only reagent or cell-culture supplement not for human consumption, is prohibited in competitive sport, and does not qualify as a lawful dietary supplement.
Educational use only. This article describes what the published scientific and clinical literature reports about IGF-1 LR3. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
